Io Therapeutics owns a diverse portfolio of issued and pending US and international patents and patent applications for methods of use its RXR agonist compound IRX4204, for treatment of cancers (including lung, breast, colorectal, cervical, pancreatic, prostate, hematologic); neurodegenerative diseases (Alzheimer’s, Parkinson’s, multiple sclerosis, amyotrophic lateral sclerosis, stroke, traumatic central nervous system injury, schizophrenia, aging-related neurodegeneration, and peripheral neuropathies); autoimmune/immune diseases (including rheumatoid arthritis, psoriasis, allergies, and transplantation); and diseases of cardiac and skeletal muscle (myocardial infarction and others).
The company owns issued and pending patents for methods of synthesis of IRX4204, and for analogues of IRX4204.
The company owns pending patents for use of IRX4204 for in vitro promotion of growth of neural, glial, and muscle cells in commercial production for use in auto- or allo-transplantation for treatment of neurologic and muscle diseases.
The company owns patent applications for use of IRX5183 for treatment of acute myeloid leukemias, multiple myeloma, and other cancers.
Retinoids for Potentiation of Immune Cancer Therapies
The company owns a diverse portfolio of issued and pending US and international patent applications for methods of use of various retinoid compounds for treatment of cancer patients to increase anti-cancer effects of various immune therapies, including checkpoint inhibitors and chimeric antigen receptor-modified immune cells; and for in vitro promotion of growth of chimeric antigen receptor-modified immune cells for commercial production.